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INTRODUCTION
Lung disease is a significant worldwide health problem in which mortality rates continue to rise despite significant efforts to address underlying causes (Kiley 2011) .
Approximately 235 million people suffer from asthma, chronic obstructive pulmonary disease leads to over 3 million deaths per year, and lung cancer is responsible for approximately 1.6 million deaths, being the third leading cause of death in the United States (Dela Cruz, Tanoue et al. 2011 ). With few effective treatment options for many of these conditions, there is an urgent need for improved therapeutic approaches.
Detailed studies of lung pathology in patients suffering from lung disease are limited. Historically, information regarding lung-specific responses to therapeutic compounds has been derived from the study of lung tissue at autopsy or from animal models (Craig, Dunn et al. 1975 , Elliott, Osterlind et al. 1987 , Yokose, Ito et al. 2000 , Pemberton, Kobayashi et al. 2006 . Consequently, many researchers are now turning to in vitro humancell-based culture models to answer basic questions related to cellular responses in the lung.
One of the earliest laboratory models used to study lung development was focused on the formation of alveolar-like tissue structures (Yu, Fang et al. 2007 ). More recent efforts have focused on models of the pulmonary-alveolar-capillary barrier (Bhattacharya and Matthay 2013, Jaworski and Redlarski 2014) . These simple culture models comprising one or two cell types were not able to recapitulate organ-level functionalities that are required for the development of meaningful disease models. An emerging approach to mimicking organ level functionality in a culture model is the development of human "organs-on-chips" (Li, Valadez et al. 2012 , Bhatia and Ingber 2014 , Esch, Bahinski et al. 2015 . These organmimetic microdevices enable the study of complex human physiology in an organ-specific This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on November 19, 2015 as DOI: 10.1124 at ASPET Journals on June 25, 2017 dmd.aspetjournals.org Downloaded from context and, more importantly, they provide the opportunity to develop specialized in vitro human disease models capable of impacting drug development.
Significant efforts have been aimed at the development of in vitro models for the human airway (Huang, Wiszniewski et al. 2013 , Nesmith, Agarwal et al. 2014 . Progress in basic mechanisms of important airway functions (Thompson, Barclay et al. 2006 , Pohl, Hermanns et al. 2009 , Prytherch, Job et al. 2011 , Sellgren, Butala et al. 2014 , Farsani, Deijs et al. 2015 has been obtained with these models; however, many airway models rely on cell lines rather than human primary epithelial cells, and are often cultured in laboratory systems that are difficult to scale or implement in an automated fashion.
We report a human airway model and its interaction with glucocorticoids in an airliquid-interface (ALI) culture system that can be easily multiplexed. The model is demonstrated in a microfluidic platform that offers a flexible format capable of accepting a wide variety of module types and sizes. Further, the platform enables circulation of the cell culture media in a manner that permits dynamic control over mixing and sampling; this feature also permits interactions between the airway model and other compartments and organ models. This platform model adds a new dimension in functional capability over static culture systems, namely the ability to manipulate the mixing times of drugs introduced into the module and any concentration gradients that are present for the drugs, metabolites or other chemical species in the reactor system. In this regard, dynamic platform conditions more closely represent physiological conditions, in which vascular and interstitial flow and drainage into the lymphatic system can strongly influence the transport of drugs and other species. Successful exploitation of this human airway model requires attention to a number of factors that affect the ability of lung cells to adapt to in vitro conditions. For example, DMD # 66365 glucocorticoids promote differentiation and prolong the life of human cells in cultures (Smith, Torday et al. 1973) . Therefore, for this study, hydrocortisone (HC) and cortisone (C) were used to support relevant physiological functions of the lung.
Here we describe a microfluidic platform on which primary human lung cells were seeded into compartments coated with collagen, forming an ALI, and flow-through channels underneath the ALI provided a fluid path for mixing and stirring of media between media changes. Cell differentiation was evaluated by immunohistochemistry, transepithelial electrical resistance (TEER), and mucus secretion values. In vitro glucocorticoid concentration versus time data were characterized using multi-compartmental pharmacokinetic modeling, and real time PCR was performed to evaluate 11HSD1 and 11HSD2 in the presence of glucocorticoids.
MATERIALS AND METHODS
Chemicals and reagents
Deuterated HC, used as internal standard, was obtained from Cambridge Isotope Laboratories (Tewksbury, MA, USA). High performance liquid chromatography (HPLC) grade (≥ 99.9 %) methanol, chloroform, formic acid (FA), molecular biology grade dimethyl sulfoxide, HC, and C were purchased from Sigma Aldrich (St. Louis, MO, USA). The standard solution used to tune and calibrate the quadruple time-of-flight (QTOF) mass spectrometer was acquired from Agilent Technologies (Santa Clara, CA, USA). HPLC grade acetonitrile (ACN) was from EMD Millipore Corporation (Billerica, MA). Distilled water was prepared in-house with double distillation.
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Cell culture
Cryopreserved normal human bronchial epithelial (NHBE) cells were purchased from Lonza (CC2540, lot 307177). After expansion with bronchial epithelial growth medium (BEGM; Lonza, Walkersville, MD, USA), cells were seeded onto human collagen-IV (Sigma Aldrich, St. Louis, MO, USA) coated 6.5 mm transwell inserts (Costar, Corning, NY, USA) at a density of 1x10 5 cells per insert. After 3 days, cultures were exposed to ALI. DMD # 66365 These transwell devices were placed into a custom microfluidic platform comprising 4 locations, so that 4 replicates of the airway model could be maintained simultaneously (Fig. 1) . Each location in the platform permits insertion of the transwell into a precisionmachined slot, and a fluid network path in which flow is circulated in a controlled manner through the lower chamber of the transwell module underlying the tracheobronchial culture model at ALI. The platform is precision-machined from polysulfone and has an integrated set of flow-control pumps that are pneumatically driven; each pump contains a solenoid valve (Lee Valve Co., Westbrook, CT, USA) that addresses a fluid displacement chamber, enabling precise one-way flow through the circuit. In the experiments described here, the 
Mucus and TEER evaluation
Lungs were evaluated for TEER and mucus secretion after exposure to dynamic conditions. Mucus was harvested apically and quantified using an alcian blue colorimetric assay. Briefly, alcian blue (Richard Allan Scientific, Kalamazoo, MI, USA) was added to samples and equilibrated for 2 h. Next, samples were centrifuged washed in a resuspension buffer, followed by dissociation with 10% SDS (Sigma Aldrich, St. Louis, MO, USA) solution. Absorbance was read with a microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 620 nm. Mucin standard was prepared from bovine submaxillary glands (Sigma Aldrich, St. Louis, MO, USA). For detailed methods on collection and quantification of mucus see Lever, Park, et al., 2015. This article has not been copyedited and formatted. The final version may differ from this version. TEER was measured using a 24-well EndOhm chamber and an ohmmeter (WPI, Sarasota, FL, USA). Transwell inserts were placed into the EndOhm chamber with PBS buffer in both the apical and basal compartments.
LC-MS based metabolite profiling
Metabolite profiling was performed as previously described (Sarkar, Rivera-Burgos et al. 2015) . Briefly, media samples were spiked with deuterium-labeled HC (d 4 -HC) to a final concentration of 50 nM, extracted with cold methanol and chloroform at a 1:4 ratio and kept in ice for two min. The samples were vortexed for 20 sec, kept at -20 °C for 30 min, vortexed and centrifuged. The organic layer was collected, dried and resuspended in 2% ACN containing 0.1% formic acid.
Liquid chromatography-mass spectrometry (LC-MS) analysis using an Agilent 6530
Accurate-Mass LC-QTOF mass spectrometer with an Agilent jet stream electrospray ionization source coupled to an Agilent 1290 ultra-high-performance liquid chromatography (UHPLC) system was performed on the resuspended samples. Parameters and conditions can be found in detail in Sarkar, Rivera-Burgos, et al., 2015 . In summary, the column was an Agilent Extend-C18 (2.1 × 50 mm, 1.8 μm; Agilent Technologies, Santa Clara, CA, USA); the column temperature was 40 °C; mass spectra were collected in positive ion mode between m/z 70 and 1000 at 2 scans/sec; ion spray voltage was 3800 V; heated capillary temperature was 350 °C; drying gas was 8 L/min; nebulizer was 30 psi; sheath gas temp was from 2% to 95% B over 12 minutes, at 0.4 mL/min.
The mass spectral data were processed using Agilent Mass Hunter qualitative analysis software (v. B.06). Extracted ion chromatograms were used to obtain the peak areas for the internal standard and the different glucocorticoids. The Agilent molecular feature extractor and manual interpretation were used to characterize the different metabolites.
Microsoft Excel 2011 and GraphPad PRISM software were used to further process and plot the data. Metabolite identification was based on targeted tandem mass spectrometry (MS/MS) analysis and metabolic pathway analysis with the KEGG database (http://www.genome.jp/kegg/; http://metlin.scripps.edu/index.php).
Each of the two biological well replicates was extracted twice for technical variation assessment and each sample was run twice in positive ion mode in the RP-UHPLC-QTOF-MS for instrumental variation evaluation (Supplemental Fig. 1 ). The analytical validation of this LC-MS method was previously described (Sarkar et al., 2015) and parameters have been summarized in Supplemental Table 1 .
In vitro characterization of parent glucocorticoid disposition: Pharmacokinetic modeling
HC-to-C and C-to-dihydrocortisone (diHC) lung bioreactor data were modeled separately with 2-compartment pharmacokinetic models for the parent drugs HC and C, respectively, and a single compartment for the metabolites C and diHC, respectively, using the SAAM II software system (SAAM Institute, Seattle, WA) (Barrett et al., 1998; Meissner et al., 2013) . To model these data, the parent drug dose was a molar amount and the plasma parent drug and metabolite concentrations were molar concentrations. The pharmacokinetic parameters describing parent drug disposition were determined first. After finalizing the fit of the pharmacokinetic model to parent drug data, the parameters of the model were fixed and a model was fit to the metabolite data, with the formation of metabolite modeled as a fraction of the elimination clearance of the parent drug in those models (i.e., parent drug elimination clearance was set equal to the sum of clearance by metabolism to the measured metabolite plus the clearance by any other mechanisms). After finalizing the fit of the pharmacokinetic model to metabolite data, parameters were released and the fit of the combined parent drug to metabolite model was finalized. The SAAM II objective function used was the extended least-squares maximum likelihood function using data weighted with the inverse of the model-based variance of the data at the observation times. Model misspecification was sought by visual inspection of the measured and predicted drug concentrations versus time relationships. Model fits to the data were assessed on the basis of the coefficients of variation associated with the adjustable parameters for each model (Metzler CM, 1986 ).
Gene expression
Total RNA was isolated with miRNeasy mini kit (Qiagen, Valencia, CA, USA). 
RESULTS
Presence of lung-specific cell subtypes
NHBE cells form a pseudostratified epithelium with a mucociliary phenotype when differentiated at an air-liquid interface (Mathis, Poussin et al. 2013) . Immunohistochemistry was used to validate the presence of essential cell types, specifically, ciliated cells and goblet cells, after exposure to dynamic culture conditions. An antibody specific to acetylated tubulin was used for ciliated cell determination. Figure 2A depicts a population of ciliated cells (green) located on the apical surface of cultures exposed to flow and the expression was maintained. F-actin staining (red), also shown in Fig. 2A , reveals a tight, cobblestone morphology typical of well-differentiated NHBE cells in vitro. In Figure 2B , positive staining for Muc5AC (green) confirmed the presence of goblet or mucus-producing cells. Table   1 ).
TEER and mucus production
Mucus secretion was also evaluated as a baseline function. Mucus production remained stable for all cultures maintained in dynamic conditions with either HC or C (8 ± 1 g/day and 7 ± 1 g/day, respectively; Table 1 ). These results indicate that baseline functions, such as epithelial resistance and mucus secretion, were maintained. 
Glucocorticoid disposition in a human airway epithelium lung model
The distribution and elimination of the parent drugs HC and C were well characterized by two compartmental pharmacokinetic models ( Fig. 4A and 4B) . After 48 h, the initial 100 nM fluid HC concentration had decreased to 47 nM under flow conditions (Fig. 4C) . In order to determine the reversibility of the conversion of HC to C mediated by the enzymes 11HSD1 and 11HSD2, a similar experiment was conducted, in which two new human airway models were dosed with C. After 48 h, the initial 30 nM C fluid concentration had decreased to 14 nM under flow conditions (Fig. 4D) .
In drug pharmacokinetic studies it is necessary to distinguish between decreases in drug concentrations due to cellular distribution and metabolism and that due to adsorption to the materials of the apparatus. To evaluate this, two other wells without cells were used as negative controls for non-specific binding experiments using the same drug doses and two of the same collection times, i.e., 1 and 48 h. The same sample preparation and analysis described for HC and C was used. Supplemental Fig. 3A and B show the concentration of HC and C respectively over a period of 48 h during which the cell-free human lung airway
at ASPET Journals on June 25, 2017 dmd.aspetjournals.org Downloaded from models were exposed to the glucocorticoids. There is no observed drop in fluid HC or C concentration over the 48 h period, which is consistent with a lack of significant adsorption to the culture system or platform fluidic circuit. Therefore, any decrease in the concentration of HC or C observed in the pharmacokinetic studies is due to cellular distribution and metabolism.
Metabolite formation
HC is metabolized by a series of oxidation and/or reductions by either bio-reductive or oxidoreductive enzymes such as 5/-reductases, 20-/ oxidoreductases, 11HSD1, and 11HSD2. High mass accuracy, retention time, database search engines and manual interpretation of MS/MS spectra were used to elucidate the putative structures of the metabolites generated in the human airway model.
After dosing with 100 nM HC, we observed that HC was metabolized and resulted in the formation of two metabolites, which were identified as C (m/z 361.2015) (Fig. 4E ) and diHC (m/z 363.2171). A representative MS/MS spectrum of the metabolite identified as diHC is shown in Supplemental Fig. 4 together with the MS/MS spectrum corresponding to C. The MS/MS spectrum of diHC revealed an intense peak m/z 163.1119, which is presumably a signature for metabolites derived from C. When the airway was dosed with 30 nM C, a single metabolite was identified: diHC (Fig. 4F) . Figure 5A was compared to a platform under static conditions. In the latter case, media was changed every 2 days, but between media changes there was no convective fluid motion within the chamber and no opportunity to control or manipulate chemical gradients that were established in the culture system. Under dynamic circulating conditions, product formation was at least 4-times faster than for static controls (Fig. 6) 
Compartmental pharmacokinetic modeling
While their initial distribution volume was approximately equal to the fluid volume of the microfluidic platform, the total volume of distribution was slightly larger due to distribution into the cultured cells (Tables 2 and 3 ). The elimination clearance of the parent drugs HC and C were completely accounted for by metabolism to the metabolites C and diHC, respectively. The elimination half-lives of the parent drugs HC and C were 67 h and 95 h, respectively.
Gene expression of 11βHSD
Expression of 11βHSD1 and 11βHSD2 was evaluated following treatment with glucocorticoids under dynamic and static conditions (Fig.7) . 11βHSD1 mRNA expression for cultures treated with HC under dynamic flow was essentially equal to that obtained under static conditions. On the other hand, results for 11βHSD2 under dynamic conditions was approximately twice that under static conditions. For C, 11βHSD1 mRNA expression for cultures under dynamic conditions was nearly identical to expression under static conditions. For 11βHSD2 expression, dynamic conditions led to expression that was approximately 1.3-times higher than that obtained under static conditions. This article has not been copyedited and formatted. The final version may differ from this version. (Lever, Park et al. 2015 ). In the model described here, metrics to evaluate these functions were used to confirm that the lung cultures maintained in vivo-like physiology and baseline functions after exposure to dynamic flow conditions and glucocorticoid treatment. We chose to evaluate these components, as they are essential for normal lung function and critical for defending against inhaled pathogens and particulates.
Evaluation of barrier function, as measured by TEER, indicated that the epithelial integrity of our lung model was not adversely affected after exposure to dynamic flow and different glucocorticoids. Maintenance of this function is essential, as the epithelium provides a protective barrier that maintains airway homeostasis (Vareille, Kieninger et al. 2011 ). The baseline mucus production rate also remained stable for all culture conditions, indicating that cells were functioning and responding normally (Table 1) . Along with TEER and mucus, we also stained for lung specific markers, specifically ciliated cells and goblet cells. In vivo, these cell subtypes are required for mucociliary transport, a process in which inhaled pathogens are trapped and cleared from the airway (Vareille, Kieninger et al. 2011 ).
In our study, ciliated cell expression was abundant ( Fig. 2A) while expression of Muc5AC was observed for all lung cultures (Fig. 2B) . Together, these results demonstrate that the cultures maintained a differentiated phenotype after exposure to dynamic flow conditions and regardless of glucocorticoid treatment.
It is common to have glucocorticoids in the media used to seed the cells as they To exemplify the metabolic capability of the airway model for complex drug metabolism studies, a detailed characterization of glucocorticoid clearance and metabolite profiling has been completed using concentrations ranging from 100 nM down to normal physiological concentrations, i.e., 30 nM, to observe changes in the lung epithelial cultures.
We found after administration of 100 nM HC, that C was a metabolite leading to the major metabolite -diHC -as a result of further C metabolism. When dosing the cultures with 30 nM C, only diHC was identified and no HC was found, suggesting that there is conversion from HC to C but not vice versa, presumably due to dominance of 11HSD2. To confirm these results, real time PCR was performed to compare the gene expression levels of both 11HSD enzymes (Fig. 7) and in fact, 11HSD2 is more highly expressed.
The observation that metabolism was faster under dynamic conditions than for static controls is significant for drug discovery. Drug metabolism can result in the formation of highly reactive metabolites that are known to play a role in toxicity, resulting in attrition during drug development and clinical use. Thus, the earlier such reactivity is detected, the better.
There are limitations to the pharmacokinetic modeling that merit mention. Although the pharmacokinetic models of the parent drugs HC and C (Fig. 4A and 4B ) were designed to allow characterization of their elimination clearance not only to the metabolites C and diHC, respectively, but also to other possible metabolites, other metabolites were not identified in the coculture media and the clearances of HC and C were completely accounted for by metabolism to C and diHC, respectively. The validity of this modeling approach is supported by the observation that the total volume of distribution of C as a parent drug, 4.27 mL (Table 3) , is similar to that of C as metabolite, 4.0 mL (Table 2 ). In addition, sampling was not conducted long enough to allow full and accurate characterization of the pharmacokinetics of the metabolites C and diHC, which is why the elimination clearance of C is 0.03 mL/hr as a parent drug but 0.29 mL/hr as a metabolite. Finally, although diHC concentrations were measured after dosing the parent drug HC, it was not possible to model its formation from the metabolite C because the relatively few sampling times did not provide enough information to support such model complexity.
In summary, we have presented the results of an investigation of glucocorticoid fate in an in vitro system comprising primary human airway epithelial cells cultured in a microfluidic platform with circulating flow. The in vitro airway model exhibits physiologically relevant behavior including barrier function, mucus formation, and ciliated subpopulations. Clearance, metabolism and pharmacokinetics of HC and C have been evaluated in this platform. Product formation is shown to be at least 6-times faster in the microfluidic-circulating platform than in static controls, an important finding given the potential role of this platform in evaluating drug toxicity. The microfluidic-circulating platform represents a powerful tool for investigating drug fate in preclinical studies, and the dynamic behavior of this system may enable the construction of a multi-organ human platform to correlate more accurately in vitro data to in vivo clearance.
TABLES
